Raymond James Initiates Strong Buy on Taysha (TSHA) Amid Rett Syndrome Trial Momentum

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential. On October 20, Raymond James initiated coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Strong Buy rating and a $13 price target, aligning with the broader analyst consensus. Raymond James Initiates Strong Buy on Taysha (TSHA) Amid Rett Syndrome Trial Momentum Pressmaster/Shutterstock.com The firm cited promising Phase 1/2 REVEAL trial results for Rett syndrome and positiv ...